Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Kraus WL, Lis JT. PARP goes transcription. Cell 113(6), 677–683 (2003).
  Medline CASGoogle Scholar
• 2 Schreiber V, Dantzer F, Ame J-C, De Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7(7), 517–528 (2006).
  Medline CASGoogle Scholar
• 3 De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem. Pharmacol. 84(2), 137–146 (2012). • An updated understanding of Poly-ADP-ribosyl polymerase (PARP) must include its many roles in DNA repair. Placement into the base excision repair pathway is an artifact of available genetic techniques at the time of PARP discovery.
  MedlineGoogle Scholar
• 4 Kim MY. Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal. Genes Dev. 19(17), 1951–1967 (2005).
  Medline CASGoogle Scholar
• 5 Kotz J. PARP target practice. Science-Business eXchange 5(13), 323 (2012).
  Google Scholar
• 6 Liscio P, Camaioni E, Carotti A, Pellicciari R, Macchiarulo A. From polypharmacology to target specificity: the case of PARP inhibitors. Curr. Topics Med. Chem. 13(23), 2939–2954 (2013).
  Medline CASGoogle Scholar
• 7 Wahlberg E, Karlberg T, Kouznetsova E et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat. Biotechnol. 30(3), 283–288 (2012).
  Medline CASGoogle Scholar
• 8 Murai J, Huang SYN, Das BB et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72(21), 5588–5599 (2012).
  Medline CASGoogle Scholar
• 9 Murai J, Huang SYN, Renaud A et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 13(2), 433–443 (2013). • PARP-1 can be trapped on the DNA in the presence of PARP inhibitors.
  MedlineGoogle Scholar
• 10 Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat. Cell Biol. 16(1), 2–9 (2013).
  Google Scholar
• 11 Aredia F, Scovassi AI. Poly(ADP-ribose): a signaling molecule in different paradigms of cell death. Biochem. Pharmacol. 92(1), 157–163 (2014).
  Medline CASGoogle Scholar
• 12 “Talazoparib” CID = 44819241. https://pubchem.ncbi.nlm.nih.gov/compound/44819241
  Google Scholar
• 13 “Olaparib” CID = 23725625. https://pubchem.ncbi.nlm.nih.gov/compound/23725625
  Google Scholar
• 14 “Velaparib” CID = 11960529. https://pubchem.ncbi.nlm.nih.gov/compound/11960529
  Google Scholar
• 15 “Niraparib” CID = 24958200. https://pubchem.ncbi.nlm.nih.gov/compound/24958200
  Google Scholar
• 16 “Rucaparib” CID = 9931954. https://pubchem.ncbi.nlm.nih.gov/compound/9931954
  Google Scholar
• 17 Liu X, Shi Y, Maag DX et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin. Cancer Res. 18(2), 510–523 (2011).
  MedlineGoogle Scholar
• 18 Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit Poly(ADP-Ribose) polymerase in vitro. Clin. Cancer Res. 18(6), 1655–1662 (2012).
  Medline CASGoogle Scholar
• 19 Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat. Rev. Clin. Oncol. 7(12), 702–707 (2010).
  Medline CASGoogle Scholar
• 20 Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12(1), 68–78 (2011).
  MedlineGoogle Scholar
• 21 Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2), 171–182 (2002).
  Medline CASGoogle Scholar
• 22 Mccann KE. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer. Curr. Opin. Obstet. Gynecol. 30(1), 7–16 (2018).
  MedlineGoogle Scholar
• 23 Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 12(12), 1439–1456 (2016).
  CASGoogle Scholar
• 24 Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33(3), 244–250 (2015).
  Medline CASGoogle Scholar
• 25 Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366(15), 1382–1392 (2012).
  Medline CASGoogle Scholar
• 26 Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised Phase II trial. Lancet Oncol. 15(8), 852–861 (2014).
  Medline CASGoogle Scholar
• 27 Ledermann J, Oza AM, Lorusso D et al. ARIEL3: a Phase III, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC). Ann. Oncol. 28(Suppl. 5), v605–v649 (2017).
  Google Scholar
• 28 Mirza MR, Monk BJ, Herrstedt J et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375(22), 2154–2164 (2016).
  Medline CASGoogle Scholar
• 29 Pujade-Lauraine E, Ledermann JA, Penson RT et al. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the Phase III SOLO2 study. Gynecol. Oncol. 145, 219–220 (2017).
  MedlineGoogle Scholar
• 30 Robson M, Im S-A, Senkus E et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377(6), 523–533 (2017). •• The Phase III OlympiAD trial led to the first US FDA approval for PARP inhibitors for breast cancer.
  Medline CASGoogle Scholar
• 31 Litton JK, Rugo HS, Ettl J et al. Talazoparib in patients with advanced breast cancer and a germline BRCA Mutation. N. Engl. J. Med. 379(8), 753–763 (2018). •• The Phase III EMBRACA trial showed a median progression-free survival advantage for patients with germline BRCA1/2 mutations and metastatic breast cancer treated with talazoparib versus physcian’s choice of chemotherapy.
  Medline CASGoogle Scholar
• 32 Mccann KE, Hurvitz SA. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context 7, 212540 (2018).
  MedlineGoogle Scholar
• 33 Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 5(11), 1137–1154 (2015).
  Medline CASGoogle Scholar
• 34 Clinical Trials Database: NCT01989546. https://ClinicalTrials.gov/show/NCT01989546
  Google Scholar
• 35 Clinical Trials Database: NCT01286987. https://ClinicalTrials.gov/show/NCT01286987
  Google Scholar
• 36 De Bono J, Ramanathan RK, Mina L et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov. 7(6), 620–629 (2017).
  Medline CASGoogle Scholar
• 37 Clinical Trials Database: NCT02034916. https://ClinicalTrials.gov/show/NCT02034916
  Google Scholar
• 38 Turner NC, Telli ML, Rugo HS et al. Final results of a Phase II study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). J. Clin. Oncol. 35(15 Suppl.), 1007–1007 (2017).
  Google Scholar
• 39 Litton JK, Scoggins M, Whitman GJ et al. A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345. J. Clin. Oncol. 35(15 Suppl.), TPS595–TPS595 (2017).
  Google Scholar
• 40 Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85(5), 365–376 (1993).
  Medline CASGoogle Scholar
• 41 Clinical Trials Database: NCT02286687. https://ClinicalTrials.gov/show/NCT02286687
  Google Scholar
• 42 Clinical Trials Database: NCT02401347. https://ClinicalTrials.gov/show/NCT02401347
  Google Scholar
• 43 Clinical Trials Database: NCT01945775. https://ClinicalTrials.gov/show/NCT01945775
  Google Scholar
• 44 Litton JK, Scoggins M, Ramirez DL et al. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 3, 49 (2017).•• This neoadjuvant study is encouraging for defining a role for PARP inhibitors in the curative setting in breast cancer patients.
  Medline CASGoogle Scholar
• 45 Wainberg ZA, Hecht JR, Konecny GE et al. Safety and efficacy results from a Phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies. Cancer Res. 76(14 Suppl), Abstract CT011 (2016). • Most clinical trials combining PARP inhibitors with chemotherapy have started with full-dose chemotherapy and dose-escalated the PARP inhibitor, with a failure to achieve a dose of PARP inhibitor shown to be effective as a monotherapy due to myelosuppressive toxicities. In this trial, the effective monotherapy dose of talazoparib was utilized, and chemotherapy started at a low dose and was escalated. PARP inhibitors could be considered chemosensitizers.
  Google Scholar
• 46 Quinet A, Lemaçon D, Vindigni A. Replication fork reversal: players and guardians. Mol. Cell 68(5), 830–833 (2017).
  Medline CASGoogle Scholar
• 47 Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12(1), 68–78 (2012).
  CASGoogle Scholar
• 48 Litton JK, Rugo HS, Johannes Ettl J et al. Abstract GS6-07: a Phase III trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA-mutation. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 5–9 December 2017.
  Google Scholar
• 49 Osoba D, Aaronson N, Zee B, Sprangers M, Te Velde A. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual. Life Res. 6(2), 103–108 (1997).
  Medline CASGoogle Scholar
• 50 Clinical Trials Database: NCT03150576. https://ClinicalTrials.gov/show/NCT03150576
  Google Scholar
• 51 Dent RA, Lindeman GJ, Clemons M et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 15(5), R88 (2013).
  MedlineGoogle Scholar
• 52 Rugo HS, Olopade OI, Demichele A et al. Adaptive randomization of veliparib–carboplatin treatment in breast cancer. N. Engl. J. Med. 375(1), 23–34 (2016).
  Medline CASGoogle Scholar
• 53 Loibl S, O'Shaughnessy J, Untch M et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, Phase III trial. Lancet Oncol. 19(4), 497–509 (2018).
  Medline CASGoogle Scholar
• 54 Puhalla S, Beumer JH, Pahuja S et al. Final results of a Phase I study of single-agent veliparib (V) in patients (pis) with either BRCA1/2-mutated cancer (BRCA plus), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). J. Clin. Oncol. 32(15), 2570 (2014).
  MedlineGoogle Scholar
• 55 Konstantinopoulos P, Moore KN, Sachdev JC et al. Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162). J. Clin. Oncol. 34(15 Suppl.), TPS5599–TPS5599 (2016).
  Google Scholar
• 56 Domchek S, Bang YJ, Coukos G et al. MEDIOLA: a Phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours. Ann. Oncol. 27(Suppl. 6), 359–378 (2016).
  MedlineGoogle Scholar
• 57 Clinical Trials Database: NCT00576654. https://ClinicalTrials.gov/show/NCT00576654
  Google Scholar
• 58 Huggins-Puhalla SL, Han HS, Diéras V et al. Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC). J. Clin. Oncol. 33(28 Suppl.), 155–155 (2015).
  Google Scholar
• 59 Ettl J, Quek RGW, Lee KH et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA Phase III trial. Ann. Oncol. 29(9), 1939–1947 (2018).
  Medline CASGoogle Scholar
• 60 O’Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front. Oncol. 4, 42 (2014).
  MedlineGoogle Scholar